Puma Biotechnology
PBYI
123 hedge funds and large institutions have $362M invested in Puma Biotechnology in 2020 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 38 increasing their positions, 41 reducing their positions, and 20 closing their positions.
36% more call options, than puts
Call options by funds: $4.3M | Put options by funds: $3.17M
1% less capital invested
Capital invested by funds: $364M → $362M (-$1.94M)
7% less repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 41
2.23% less ownership
Funds ownership: 91.03% → 88.8% (-2.2%)
4% less funds holding
Funds holding: 128 → 123 (-5)
20% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 20
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$11.5M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$5.25M |
| 3 |
Morgan Stanley
New York
|
+$3.64M |
| 4 |
JGC
J. Goldman & Co
New York
|
+$2.42M |
| 5 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
-$12.6M |
| 2 |
State Street
Boston,
Massachusetts
|
-$5.86M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$3.49M |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$2.26M |
| 5 |
Goldman Sachs
New York
|
-$2.12M |
PBYI Hedge Fund Activity: Q4 2020 in Review
123 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in Puma Biotechnology (PBYI) for Q4 2020, worth a combined $362M — down 0.53% from $364M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of PBYI and 16 opened new positions — a net loss of 4 holders — while 41 trimmed existing stakes and 38 added.
The largest buyer was Deerfield Management, adding an estimated $11.5M. The largest seller was Tang Capital Management, exiting entirely with an estimated $12.6M sold.
- 123 institutional investors held Puma Biotechnology (PBYI) as of Q4 2020, down from 128 in Q3 2020.
- Funds reported $362M of Puma Biotechnology stock for Q4 2020, down 0.53% quarter-over-quarter.
- 16 funds opened new Puma Biotechnology positions in Q4 2020 and 20 closed out, a net change of -4 holders.
- The largest Puma Biotechnology buyer in Q4 2020 was Deerfield Management, an estimated $11.5M added.
- The largest Puma Biotechnology seller in Q4 2020 was Tang Capital Management, an estimated $12.6M sold.
Based on aggregated 13F filings for Q4 2020.